Podcasts about wegovy

Ozempic. Wegovy. Mounjaro. If you've ever found yourself wondering, “Should I try one?”—this episode is for you.Roughly 12% of Americans have tried a weight loss drug, yet up to 85% stop within two years. Most regain the weight, and many feel worse than before. So why do these drugs seem so promising—and why don't they work long-term?Today you will learn…- How GLP-1 drugs actually work - The dark side of GLP-1s that no one mentions- What happens when you stop taking weight loss medications - The sustainable alternative to healing food noise

You've done the meal prep, the steps, the Peloton rides after bedtime stories—yet the scale is not "scaling". Now everybody from your group chat to Serena Williams is talking about “the shot.” In this episode, Dr. Stephane Hack, MD, MPH, breaks down GLP-1 medications (like Ozempic, Wegovy, and Zepbound) in plain language: what they are, how they work, who they're really for, and what risks often get glossed over. We'll talk motherhood, metabolism, perimenopause, endometriosis, fertility, and the pressure to “snap back". Whether you're a busy professional juggling work, marriage, kids, or just trying to feel at home in your own body again, this conversation is your judgment-free zone to get informed before you decide what's next for your body.

PODCAST LAS NOTICIAS CON CALLE DE 18 DE NOVIEMBRE 2025 - Saqueo de barcaza a PR fue desde el miércoles pasado - Cuarto Poder  Epstein sería firmado por Trump dice Casa Blanca - Politico Último día de sesión legislativa - El Vocero Se estremece el mercado mundial y la bolsa de valores, Suben sueldo de empleados de corrección a 3 mil mensuales - El Vocero 2 millones cuesta el boquete del superacueducto - El Vocero Reforma contributiva para el 2026 dicen legisladores del PNP que dicen estar contra una Extraordinaria - El Vocero ICE dice que llevará más personal de seguridad a operativos migratorios - El Vocero ONU acepta plan de paz de Trump para Gaza, Israel y Egipto ayudarán a la policía Palestina - PBS Bajan precio de Ozempic y Wegovy a 349 y a 199 para primeros pacientes por dos meses - AxiosCállate puerquita le dice Trump a periodista - CNNA los federales Rodz Veve por filtraciones de Procuradora de la Mujer - El Vocero Redefinen lo que debe ser un fondo de ley 60 para que realmente genere inversión en PR - El Vocero El papá de LUMA llega a PR - El Nuevo Día LUMA dice que va a duplicar empleados, bueno, sus dueños - El Nuevo Día Todavía no han terminado de liquidar a Integrand y Real Legacy - El Nuevo Día Quedan reclamaciones de seguros del huracán María todavía en los tribunales - El Nuevo Día Otra vez paralizado el caso del Horned Dorset por ley de quiebras - El Nuevo Día No hay casas para vender y los precios siguen en históricos 227 mil - El Nuevo Día Recuerdan a Karla Michelle y piden ni una bala más al aire - Primera HoraLa Junta dice que PR necesita supervisión o volverán al déficit - Metro En problemas el Bitcoin bajando a 91 mil USA venderá a Arabia F-35 aunque inteligencia advierte que eso ayuda a China - Fox News Incluye auspicio 

This week, I'm diving into a fascinating piece of research I spotted in The Week; a meta-analysis of 82 studies from University College London looking at how physical activity affects menstrual pain and PMS. The findings are striking: women who move less have a 67% higher risk of painful periods and a 22% higher risk of PMS symptoms.But this episode isn't just about the data, it's about how it intersects with real life. I'm sharing my own PCOS story, from being diagnosed at 17 and barely moving, to being 47, active, and experiencing far fewer symptoms. We'll also unpack the confused (and sometimes misleading) world of cycle-syncing advice online, including what's genuinely helpful and what's been oversimplified by social media.Plus, I'm talking about the growing role of GLP-1 medications like Ozempic and Wegovy: where they can fit into women's hormonal and metabolic health, and why it's not a choice between medication or movement. For many women, the two work beautifully together.Whether you experience period pain, PMS, PCOS, or you're simply curious about how movement and hormones overlap, this episode is all about giving you tools, not rules. Think of it as a realistic, compassionate look at women's health, packed with evidence, lived experience, and nuance.In this episode:The UCL study linking activity levels to menstrual pain and PMSMy PCOS journey: 17 vs 47What cycle syncing gets right, and very, very wrongWhy influencers and experts like Dr Stacy Sims and Dr Vonda Wright create both empowerment and confusionHow exercise supports hormones, mood, metabolism, and overall cycle healthA realistic approach to training across the menstrual cycleWhere GLP-1 medications fit into the pictureWhy movement is a powerful tool but never the only one.Hey! Why not share your thoughts and insights to make your listening experience even better. Complete this listener survey to tell me what you want to hear: http://bit.ly/theemmagunsshow-survey Hosted on Acast. See acast.com/privacy for more information.

Het Exclusive OTP Discounts! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, you will learn:What are peptides? The basic science of these "small proteins" and how they signal cells to function.GLP-1s Explained: How drugs like Ozempic and Mounjaro were originally developed for diabetes but have gained popularity for weight loss.The Big Picture: Peptides are used for more than just weight loss—Dr. Jones discusses their use in migraines, bone building, and studies for ALS and MS.The Weight Loss Surge: Why obesity and its link to chronic diseases (diabetes, hypertension, high cholesterol) is fueling interest in these drugs.The Critical Component: Why a GLP-1 shot is not enough—the medication must be combined with good nutrition, exercise, and psychological health for lasting success.Protein is Key: The importance of adequate protein intake and strength training to maintain muscle mass and prevent hair loss associated with rapid weight loss.The Inflammation Link: How GLP-1s can decrease inflammation (like high cortisol) which often causes stubborn abdominal fat and joint pain.Dispelling Myths: Separating real side effects (like minor hypoglycemia) from media fear-mongering (like blindness), and understanding that hair loss is often due to rapid weight loss, not the drug itself.Next Steps: Where to start if you are interested in peptide therapy and the importance of a consult with a pharmacist.Resources Mentioned:Your Health Wellness Team: Contact the team to schedule a consultation on weight loss goals and peptide therapy. www.YourHealth.Org

El presidente Trump dijo que está dispuesto a dialogar con el gobernante de Venezuela: Nicolás Maduro, luego de que el Departamento de Estado anunciara que se prepara para designar al 'Cartel de los Soles'  como una organización terrorista extranjera.En otras noticias: Charlotte, Carolina del Norte, fue escenario de varios operativos de migración por parte de la patrulla fronteriza. Mas de 130 personas fueron arrestadas.Así mismo en un club nocturno en San Antonio, Texas arrestaron a 140 indocumentados entre los que se encontrarían menores de edad y miembros del 'Tren de Aragua' según las autoridades.El presidente Trump dijo que autorizará la publicación de los archivos Epstein. 

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35, que arranca en un contexto de mayor aversión al riesgo por parte de los inversores. En el análisis de mercados, Pablo García (DIVACONS–Alphavalue) destaca la fuerte búsqueda de refugio en la renta fija, la presión sobre el sector tecnológico tras nuevas ventas masivas y las dudas crecientes sobre el rumbo de la Reserva Federal y los tipos de interés. Además, analizamos el recorte de precios de Wegovy por parte de Novo Nordisk, la decisión de Ucrania de adquirir 100 aviones de combate Dassault Rafale y el movimiento estratégico del Banco Santander, que entra en el circuito de liquidez de la Fed para reforzar su crecimiento en Estados Unidos. Cerramos la hora con el consultorio de bolsa de Javier Alfayate, que responde a las dudas de los oyentes sobre estrategia y valores destacados del momento.

Welcome to Ozempic Weightloss Unlocked. Today, we are diving into the latest news and updates on Ozempic, a drug reshaping how we think about weight loss, health, and lifestyle.In the past year, millions of people have turned to Ozempic, part of a group of medications called GLP-1 receptor agonists. Originally created to manage blood sugar for people with type 2 diabetes, Ozempic's appetite-suppressing effects have made it a sought-after tool for weight management. According to the Pennington Biomedical Research Center, these medications were developed from a compound first found in the saliva of the Gila monster lizard. It is amazing to think that a hormone from a desert reptile is now changing lives in clinics around the world.One of the most important updates is accessibility. The White House recently announced a deal with drug makers Eli Lilly and Novo Nordisk to cut prices for Ozempic and related drugs. The average monthly cost, once more than one thousand dollars, could now be as low as fifty to three hundred fifty dollars a month, depending on your insurance. Kim Fisher of the UC Davis Innovation Institute for Food and Health says around one in eight adults in the United States—about forty-one million people—have already used GLP-1 drugs. Lower prices open the door for many more people to take advantage of these treatments.For listeners looking for alternatives to injections, there is more good news. Novo Nordisk recently released results from a study on an oral pill version of Ozempic's sister drug, Wegovy. The New England Journal of Medicine reports that this once-daily pill resulted in an average weight loss of sixteen point six percent—almost identical to the weekly injection. While the pill is not yet approved by the Food and Drug Administration, it may become a game-changer for those seeking a needle-free option. Novo Nordisk says they hope to set a new benchmark for oral weight loss medications pending approval.If you are wondering whether these drugs only affect the scale, the answer is no. According to research from UC Davis and the University of California San Diego, GLP-1 drugs not only promote weight loss, but may also offer broader health benefits. Some of the latest studies show that these medications can lower cardiovascular risk, benefit blood pressure, and even reduce the risk of major events like heart attacks and stroke.Researchers at UC San Diego found that GLP-1 use among people with colon cancer was tied to much lower death rates—fifteen point five percent for those on the drugs, versus thirty-seven point one percent for those who were not. While the exact reasons are still being studied, experts believe these medications reduce inflammation, improve insulin sensitivity, and might even directly inhibit the growth of cancer cells.The way GLP-1 drugs work is by mimicking a natural hormone produced in your gut after eating. They help your body feel full longer, lower blood sugar, and curb cravings—especially for sweets and fatty foods. Patients often report that the constant mental chatter about food is quieter, making it easier to stick to healthy habits.With all the benefits, it is important to mention common side effects. Many users experience nausea, vomiting, or diarrhea, particularly when starting or increasing doses. Doctors recommend pairing treatment with a nutrient-dense diet, regular exercise, and enough protein to help preserve muscle mass.Experts are also discussing the need for ongoing research into the long-term effects and best practices for managing side effects. As these drugs become more widely used, scientists are working to make sure weight loss translates into lasting improvements for health and well-being.That is all for today's episode of Ozempic Weightloss Unlocked. Thank you for tuning in. To stay up to date on the next wave of news and breakthroughs, remember to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Han vuelto los datos a Estados Unidos tras volver a abrir el Gobierno federal. El gasto en construcción repuntó de forma inesperada en agosto. Lo hace impulsado por las renovaciones de viviendas porque el aumento de los tipos hipotecarios sigue pesando sobre la construcción de viviendas unifamiliares. El incremento es del 0,2%. Se esperaba caída del 0,1%. Hay, por otro lado, comentarios desde la Reserva Federal. El vicepresidente Jefferson para nada refuerza la idea de recorte de tipos en diciembre. Dice que el equilibrio cambiante de riesgos subraya la necesidad de avanzar despacio a medida que el banco central se acerca a su tipo neutral. En lo corporativo, Lilly cae después de que su rival Novo Nordisk lance Wegovy a 349 dólares; HP cae tras la rebaja de Morgan Stanley a "infraponderar" y Alphabet al alza mientras Berkshire revela una nueva participación en la reestructuración de su cartera. El mercado lo analizamos esta hora con Marc Ribes, de Blackbird. Hablamos, por otro lado, de Solaria y de lo que ha dado de sí el Consejo de Política Fiscal y Financiera. Tras el Cierre, Pistas Técnicas.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it's metabolic medicine, mythbusting, and science-backed encouragement for your journey.Key Questions AnsweredWhat is the “selfish brain” and how does it really impact blood sugar and diabetes risk?Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you're using them?If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper's individualized care—and can you taper off meds and maintain results?What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?Key TakeawaysMetabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.Dr. Cooper's Actionable TipsAlways dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.If you're prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don't risk unregulated online compounds. Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.Stay consistent and compassionate—focus on small improvements over extremes and absolutes.Notable Quote“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramGeneric medication access: Mark Cuban Cost Plus DrugsZepbound direct: Lilly DirectAdditional info: Novocare for WegovyFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Send us a textThe mic comes back on and we don't ease in—we tell the truth. A cosy Christmas village spins in the background while we unpack a year that bent our capacity, stalled our schedule, and still pushed us toward braver choices. We decide to keep the show alive with a slower cadence, not out of defeat, but because sustainability is a skill worth practising.The heart of the conversation is a major health update: approval into a bariatric surgery program with a likely date within the next year. We dig into the fear that rides shotgun—fear of death, fear of change, fear of lifelong rules—and the hope that keeps us moving. This isn't an easy way out; it's a structured, demanding path with supplements, labs, hydration, and habits that compound over time. Alongside that comes the messy reality of weight stigma and access: Saxenda costs spike, insurance falls short, a switch to Wegovy helps, and Vyvanse quiets binge urges and ADHD‑fuelled food noise in surprising ways.We also name what many avoid. Borderline personality disorder shows up as people pleasing, conflict avoidance, and a fragile sense of self. Therapy helps and sometimes hurts; progress isn't linear. We talk about stepping back from social media for mental health, planning to document the bariatric journey on YouTube with safer comment boundaries, and finding small joys—sourdough starters, cranberry‑brie pull‑apart bread, and a child's sticky‑sweet cameo—that make the hard days softer. There's a candid story about foot pain, a podiatrist's nod that stings, and a physio's reframing that reminds us weight can be a factor without being the whole story.If you've felt unseen by healthcare, wrestled with food noise, or needed permission to slow down without giving up, this one's for you. Listen, share with a friend who needs a compassionate nudge, and leave a rating or review so more people can find these conversations. Subscribe to catch the bariatric prep series and our year‑end wrap as we rebuild a kinder rhythm together.Support the showDo you have a story you would like to share? Send it to us at theweightingroompc@gmail.comDisclaimer: We are not Medical professionals and all views and opinions are our own.

Han vuelto los datos a Estados Unidos tras volver a abrir el Gobierno federal. El gasto en construcción repuntó de forma inesperada en agosto. Lo hace impulsado por las renovaciones de viviendas porque el aumento de los tipos hipotecarios sigue pesando sobre la construcción de viviendas unifamiliares. El incremento es del 0,2%. Se esperaba caída del 0,1%. Hay, por otro lado, comentarios desde la Reserva Federal. El vicepresidente Jefferson para nada refuerza la idea de recorte de tipos en diciembre. Dice que el equilibrio cambiante de riesgos subraya la necesidad de avanzar despacio a medida que el banco central se acerca a su tipo neutral. En lo corporativo, Lilly cae después de que su rival Novo Nordisk lance Wegovy a 349 dólares; HP cae tras la rebaja de Morgan Stanley a "infraponderar" y Alphabet al alza mientras Berkshire revela una nueva participación en la reestructuración de su cartera. El mercado lo analizamos esta hora con Marc Ribes, de Blackbird. Hablamos, por otro lado, de Solaria y de lo que ha dado de sí el Consejo de Política Fiscal y Financiera. Tras el Cierre, Pistas Técnicas.

Microdosing GLP-1s like Ozempic and Wegovy is the latest buzz in the health world — but is it safe, effective, or even legal? In this episode, I break down the newest research, FDA updates, and expert opinions on microdosing GLP-1 medications. Learn what the science really says, what's still unknown, and why sustainable habits will always matter more than shortcuts.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill's future.Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey's evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah's decision to speak candidly about her hesitation and subsequent experiences gives voice to a wider conversation happening both in Hollywood and across the nation. As more public figures reveal their choices, the stigma of using medication to address chronic weight struggles may begin to dissipate, helping others seek support without shame.In summary, the past week has marked a pivotal moment in the ongoing Ozempic story. The introduction of a highly effective oral pill, substantial price cuts via government negotiation, and ongoing public debate about safety, efficacy, and cultural perceptions have all contributed to growing momentum. Now, as clinicians and patients alike look ahead to a future where advanced weight management tools are both more accessible and potentially safer to use, the importance of personalized guidance and health literacy has never been clearer.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

GLP-1 weight loss drugs like Ozempic, Wegovy, and Tirzepatide are being promoted everywhere but what's missing is the full story. This episode breaks down the hidden GLP-1 side effects most women never hear about, from anxiety and dehydration to vision problems, muscle loss, and disordered eating risks. Chalene exposes how influencer affiliate programs and compounding pharmacies are fueling the hype while lawsuits and safety questions grow. You'll learn what informed consent should actually include, how to protect your metabolism, and why women over 40 need to question what's really behind this weight loss craze. Watch this episode on YouTube this Sunday!! 

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

After Dark with Hosts Rob & Andrew – Donald Trump comments on falling prices for popular weight-loss medications while reacting sharply to Nancy Pelosi's decision to retire after decades in Congress. Pelosi's legacy, family investments, and past clashes with Trump resurface as federal efforts expand access to drugs like Ozempic and Wegovy, promising savings and broader treatment options for obesity across the United States...

In this episode of the Optimal Aging Podcast, host Jay Croft talks with Dave Appel, Chief Health and Fitness Officer of KORB Health Group. KORB's mission is to bridge the gap between medicine, wellness, and fitness, creating a more integrated and accessible approach to health—especially for people over 50.They dive deep into the controversy around GLP-1s like Ozempic and Wegovy. Rather than viewing them as shortcuts or “cheating,” Dave urges fitness professionals to see these tools as gateways for deconditioned people to finally walk into the gym. This is a forward-thinking episode for anyone in fitness who wants to grow their reach and impact.Guest Name: Dave AppelBio: Dave Appel is Chief Health and Fitness Officer of KORB Health Group, where he leads the integration of GLP-1s, hormone therapy, and telehealth solutions into fitness environments. A former PE teacher and gym owner, Dave has decades of experience building programs that meet people where they are and help them transform their lives.Links:Website: https://korbhealth.comTopics CoveredGLP-1s Are Tools, Not CheatingWhy the fitness industry needs to stop judging people using medical help to get started.Dave's Journey into Integrated HealthFrom PE teacher to CrossFit owner to health-tech innovator.KORB's Mission and ModelHow KORB is bridging medicine, wellness, and fitness in gyms nationwide.The Business Case for Gym OwnersWhy GLP-1s can grow your membership and your bottom line.Serving the Over-50 PopulationMaking fitness more inclusive, accessible, and sustainable through tech and telehealth.

Thanks for listening to The Peptide Podcast.  Today we're going to talk about something that's becoming really important for anyone taking medications like Ozempic, Wegovy, or other GLP‑1 receptor agonists. You probably already know the benefits of GLP-1s—smaller appetite, better blood sugar control, and noticeable weight loss. But here's the catch: eating less can sometimes mean you're also taking in fewer essential vitamins and minerals that your body needs.  In this episode, we're going to explore how to make sure every bite counts and when it might make sense to consider supplements. Read the Full Episode Transcript: https://pepties.com/nutrient-tips-while-on-glp-1-medications/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ BioLongevity Labs (Purchase Peptides online) Use our link and enter COUPON CODE: PEPTIDEPODCAST at checkout to receive 15% off your total order https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1582&aff_sub=PEPTIDEPODCAST Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72

After Dark with Hosts Rob & Andrew – Donald Trump comments on falling prices for popular weight-loss medications while reacting sharply to Nancy Pelosi's decision to retire after decades in Congress. Pelosi's legacy, family investments, and past clashes with Trump resurface as federal efforts expand access to drugs like Ozempic and Wegovy, promising savings and broader treatment options for obesity across the United States...

Over the past several years, the rise of GLP-1 drugs such as Ozempic and Wegovy has changed the conversation around weight and obesity in the U.S. Rachel Goldman, PhD, talks about how GLP-1s work; the effects they can have on mental health; what questions to ask if you're considering trying these medications; how weight loss can shift people's relationships with their family, friends and partners; and why there's still stigma around the use of GLP-1s and how patients can navigate that. Find Dr. Rachel's new book at When Life Happens: The Mindset Shift You Need to Manage Stress, Build Confidence, and Break Free. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a text When doctors recommend weight loss, they describe the supposed benefits but remain silent about the harms—reduced metabolism, increased appetite, hormonal disruption, eating disorders, and profound mental health impacts. This ethical failure extends beyond outdated diet advice to newer interventions like GLP-1 medications, where we celebrate short-term metabolic improvements while ignoring gastrointestinal distress, financial burden, social isolation, and unknown long-term consequences. In this episode, Asher challenges the dangerous assumption that fat people should suffer to become thinner, exposing how this narrative serves the weight loss industry's profits while treating fat bodies as unworthy of basic ethical consideration in healthcare. Got a question for the next podcast? Let me know! Connect With Me WEEKLY NEWSLETTER: Get a free script when you sign up THE WEIGHTING ROOM: A community where authenticity thrives and every voice matters The CONSULTING ROOM: Get answers to all your medical questions via DM or Voice Note PLUS access to my entire library of paid resources CONSULTATION: For the ultimate transformation in your healthcare journe THE WEIGH FORWARD: For people who are being denied surgery because of their weight FREE GUIDES:Evidence-based, not diet nonsense Find me on Instagram, YouTube, and LinkedIn.

In Part 1 we looked at the basics and early research around GLP-1s for weight loss and muscle loss. In part 2 we looked at recent research around the newest GLP-1 weight loss drugs, tirzepatide (Zepbound) and semaglutide (Wegovy).In this final part of the series we are going to talk about the justifications/excuses/spin that are happening around the loss of lean muscle mass on GLP-1s. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

VALUE FOR VALUE Thank you to the Bowl After Bowl Episode Producers: harvhat, ChadF, cbrooklyn, phifer, ericpp, Boolysteed, marykateultra, NetNed, piranesi GET FREE STICKERS Send a self-addressed envelope to PO Box 410154 Kansas City, MO 64141 HyperSpaceOut.com The Great Unthinking Intro/Outro: Jaxius - Vecna FIRST TIME I EVER… Bowlers called in to discuss the First Time THEY Ever caught someone in the act. Next week, we want to hear about the First Time YOU Ever roller skated. TOP THREE 33 Fort Lauderdale airport sees 200 flight delays, 33 cancellations amid government shutdown (WFLX) Robot saves Ukrainian soldiers after 33 days behind Russian lines (The Sun) Novo Nordisk cuts weight-loss drug Wegovy price by up to 33% in India (The Economics Times) BEHIND THE CURTAIN Trump 'supports' hemp THC ban advancing in Senate, White House says (Marijuana Moment) The government shutdown may last longer because of a fight over hemp (NBC) Mamdani asked to name his favorite cannabis shop (AriMelber / Xitter) Feds take small steps away from life sentences for street-level drug selling (Filter Mag) Omaha Tribe, NE clash over cannabis policy, sovereignty (Nebraska.TV) Nebraska Governor Pillen calls tribal cannabis "poison" (FB) Omaha Tribe statement (Nebraska Examiner) ICC issues arrest warrant for ally of Philippine ex-President Duterte over drug war (Reuters / archived) Woody Harrelson says weed, acting do not go well together (YouTube) METAL MOMENT Tonight, the RevCyberTrucker brings us Decessus' Dark Flames. Follow along with his shenanigans on the Fediverse at SirRevCyberTrucker@noauthority.social ON CHAIN, OFF CHAIN, COCAINE, SHITSTAIN Square brings Bitcoin to Main Street (Square) Clark Moody Dashboard China accuses US of orchestrating $13 Billion Bitcoin hack (Bloomberg / archive) Cryptoqueen who fled China for London mansion jailed (BBC) Bitcoin user pays over $105K in BTC to send just $10 (Decrypt.co) Bitcoin minimum fee rate slashed by 90% (Decrypt.co) mempool.space KC Bitcoiners' coffee meetup at Maps 8:30 AM FRIDAY November 14 FUCK IT, DUDE. LET'S GO BOWLING Man (33) hid $14K worth of pot in toolbox (The Irish Independent / archive) 'Wicked' sequel to play for 33 straight hours at Phoenix Theatres Great Northern in Ohio (Cleveland.com) Local police chief sues owners of dogs he shot (WTVG / YouTube) Japan sends military to assist with surge in bear attacks after 12th fatality (Denver Gazette) Healthcare system apologies after over 500 living patients told they were dead via mail (FOX) Worlds of Fun coaster shut down after lap belts fail inspection (ABC / YouTube) Delta passenger trapped by 'human biohazard' seatmate who pooped his pants (Toronto Sun) Smelly socks reunite 93-year-old with missing dog (ABC / YouTube) Paris residents can enter lottery to share cemetery space with Jim Morrison, Oscar Wilde (CNN) Ward Parkway Lanes' Bob Covey maintains traditions as he nears retirement (KSHB / YouTube)  

One of biopharma's most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will see their GLP-1 drugs offered at about $350 per month.   This marks a significant discount to the current list prices of $1086 and $1350 for Lilly's obesity drug Zepbound and Novo's comparator Wegovy, respectively. No matter how low they go, however, the GLP-1 leaders can still be undercut by compounders, Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, told BioSpace this week.   Speaking of Lilly, the Indianapolis-based pharma had a busy week, reporting 20% weight loss in a mid-stage study of its amylin agonist eloralintide that William Blair analysts said “validates [the] amylin agonist class.” Lilly also netted two new partners, inking a $1.2 billion RNAi pact with SangeneBio to target metabolic diseases and licensing a genetic eye disease therapy from MeiraGTx Holdings for up to $475 million.   On the regulatory front, the FDA awarded the second round of priority review vouchers under its new Commissioner's National Priority Vouchers program. Unlike the first cohort of vouchers, which was announced in October, this group mostly consisted of products already on the market—with the exception of Lilly's orforglipron.   Finally, BioSpace dives into one the hottest trends in the immunology and inflammation (I&I) space—pipeline-in-a-product. Possibly motivated by blockbuster drugs like AbbVie's Skyrizi and Rinvoq and Regeneron and Sanofi's Dupixent, companies are optimizing shots on multiple goals in this lucrative space.  

Welcome back to The Weight Loss Collab! In today's episode, bariatric surgeon and obesity medicine expert Dr. Dovec is diving deep into the world of GLP-1 medications—those popular injectables like Ozempic, Wegovy, Zepbound, and Mounjaro that everyone's been talking about. Whether you're fresh out of bariatric surgery, struggling with weight plateaus, have a lower or higher BMI, or you're just curious if these meds might be right for you, Dr. Dovec breaks down exactly how GLP-1s work, who benefits most, potential side effects, and how to personalize your treatment for the best results. Plus, she compared options like phentermine and Contrave, and gives real talk about surgery versus medication. If you're looking for up-to-date, honest guidance on weight loss medications and a supportive community cheering you on, this episode is packed with insights and actionable advice!

In this jam-packed episode, Haylee and Jess break down everything you actually need to know about GLP-1 medications, from how they work to how they impact your gut, appetite, and metabolism.

Investor Jens Løgstrup er havnet i et stormvejr på de sociale medier. Årets klimatopmøde finder sted i den brasilianske by Belém. Nye Novo-partnere skal sælge Wegovy under andet navn. Dansk inflation. Milliardstor hvidvasksag er gået i gang. Wolt udvider samarbejde. Kæmpe skatte­let­telser til Strøgets dyreste adresser. Vært: Trine Duvander (trine.duvander@borsen.dk)

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Desde el año pasado, las grandes farmacéuticas libran una intensa batalla por dominar el mercado de los medicamentos para adelgazar. Aunque cada vez surgen nuevas empresas dispuestas a hacerse un hueco, hasta ahora el sector había estado liderado por dos grandes potencias: Novo Nordisk y Pfizer. Sin embargo, el equilibrio de poder se ha alterado con el reciente movimiento de la compañía estadounidense, que ha cerrado la compra de Metsera por 10.000 millones de dólares, consolidando su apuesta por los tratamientos contra la obesidad. La propia Metsera explicó que eligió la oferta de Pfizer debido a los posibles problemas antimonopolio que podrían haber surgido si aceptaba la propuesta de la farmacéutica danesa. La operación marca un punto de inflexión en un mercado en el que Novo Nordisk mantiene más del 50% de la cuota en Estados Unidos, impulsada por el éxito de sus fármacos basados en GLP-1. Con esta adquisición, Pfizer se adentra de lleno en el prometedor negocio de las píldoras adelgazantes, aunque su incorporación efectiva tardará en materializarse, ya que los productos de Metsera aún no están disponibles comercialmente. Aun así, la noticia no ha perjudicado a su rival: lejos de penalizarla, el mercado ha recibido positivamente el “revés” de Novo Nordisk, cuyas acciones subieron cerca de un 3% en la Bolsa de Copenhague. Los analistas ahora debaten si Pfizer ha pagado demasiado por Metsera, pero nadie duda del interés genuino de Novo Nordisk en la compañía. La firma danesa se incorporó a una negociación que ya estaba prácticamente cerrada entre Pfizer y Metsera, reactivando la competencia con una oferta inesperada. Durante un encuentro reciente en la Casa Blanca, el CEO de Novo Nordisk, Mike Doutsdar, incluso bromeó con Albert Bourla, director ejecutivo de Pfizer, sugiriéndole que aumentara su propuesta. Tras la contraoferta final de Pfizer, Novo Nordisk anunció que continuará desarrollando su propio portafolio, especialmente su versión oral del fármaco Wegovy, llamada a convertirse en el formato estrella de los medicamentos para adelgazar en 2026.

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

In this episode, Michael Smerconish discusses the political and social landscape in America, focusing on the varying definitions and acceptability of socialism. He explores the recent Democratic victories in major states and the differing approaches within the party, emphasizing the need for policies that appeal beyond urban areas. Smerconish interviews political consultant Frank Luntz on framing socialism to Middle America and delves into changing perceptions between capitalism and socialism. Additionally, he examines economic pressures and the impact of AI on the workforce, highlighting rising pessimism and comparisons with Nordic social democracies. The episode also addresses issues faced by young men today, featuring a conversation with Scott Galloway on their struggles and a call for male role models. Finally, it touches on the costs and benefits of weight loss drugs like Ozempic and Wegovy, suggesting broader access could save money and lives. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Andrew Walworth, Tom Bevan and Carl Cannon discuss new polling on candidate preferences for the 2028 presidential nomination for both parties, and this morning's reporting from Politico that Secretary of State Marco Rubio is telling close associates that he believes Vice President JD Vance is the frontrunner for the Republican nomination. Then, they talk about the role of energy prices in last Tuesday's election, and President Donald Trump's new agreement with pharmaceutical manufacturers to sell GLP-1 products like Wegovy and Zepbound at discounted prices to Medicare and Medicaid recipients. Then finally, the guys discuss the jury verdict in Washington, DC of the former Justice Department employee who threw a sandwich at a federal officer in protest last August. Plus, this week's “You Cannot Be Serious” stories. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

A 37 días del cierre del gobierno, la administración Trump confirmó que a partir de mañana se reducirá el tráfico aéreo en un 10% afectando al menos 40 aeropuertos del país. Al menos 500 vuelos serán cancelado en el primer día de la medida. Un juez de Rhode Island le ordenó al gobierno Trump conseguir los fondos necesarios para financiar los beneficios del programa de asistencia nutricional SNAP.El cierre del gobierno también podría impedir que al menos 6 millones de familias de bajos recursos puedan pagar la electricidad y la calefacción en las próximas semanas por la falta de fondos del programa LIHEAP.En otras noticias: La jueza Sarah Ellis confirmó que el comandante de la patrulla fronteriza Gregory Bovino admitió mentir sobre el uso de gas lacrimógeno. La jueza limitó el uso de la fuerza a los agente federales en Chicago.

GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# Josh Sigurdson reports on the new announcement by President Donald Trump regarding steep discounts for Ozempic, the weight loss drug. While people like RFK Jr. had for years called for subsidizing organic food rather than Ozempic, Trump feels differently. The President announced a deal with Ozempic which would involve lower prices making it more affordable and more easy to obtain via insurance policies. The problem? Ozempic is incredibly bad for you. What happened to Trump being against pharma? After giving $7 billion to Pfizer recently, he's now doubling down on his doublethink. Ozempic which comes from REPTILE VENOM (to be specific, Gila Monster venom) helps people lose weight. Though at the same time, it causes Ozempic Face which strangely makes people look like reptiles. Far worse than that, it's been tied to sudden blindness, kidney cancer, digestive issues and organ failure. The drug was meant for diabetes alongside Wegovy until it was noticed that it actually lead to weight loss. The lizard venom peptides can lead to serious side effects. This is not what people voted for when they supported Trump, but of course it's not. Why would anyone be surprised? Meanwhile, as Trump made the announcement, a man collapsed behind him. Dr. Oz ran to the rescue as RFK Jr. left the room. You can't make this stuff up... well actually you can... It's all theater. Stay tuned for more from WAM! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! SIGN UP FOR HOMESTEADING COURSES NOW: https://freedomfarmers.com/link/17150/ Get Prepared & Start The Move Towards Real Independence With Curtis Stone's Courses! GET YOUR FREEDOM KELLY KETTLE KIT HERE: https://patriotprepared.com/shop/freedom-kettle/ Use Code WAM and enjoy many solutions for the outdoors in the face of the impending reset! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Today on America in the MorningShutdown Flight Delays On a day when the Senate is hoping to vote later today on ending the government shutdown, today is the day that the FAA has ordered flights to be cut due to staffing shortages.  Yesterday, there were 200 canceled flights across the nation – today that number is expected to be above one thousand, with thousands more delayed.  Correspondent Ed Donahue reports that air traffic controllers and TSA agents received a zero paycheck for the second time since the government shutdown began, and Transportation Secretary Sean Duffy, speaking on Fox News, says the flight cutback is all about air safety.   Pelosi's Retirement After nearly 40 years on Capitol Hill, Nancy Pelosi is retiring from Congress.  Correspondent Clayton Neville reports.   Musk's Big Payday The world may soon have its first “Trillionaire.”  Joan Jones has the story of Elon Musk's payday approval granted by Tesla shareholders.   NFL Player's Suicide There is shock through the sports world after 24-year-old Dallas Cowboys defensive end Marshawn Kneeland took his own life after being involved in a police chase.  The story from correspondent Gethin Coolbaugh.   Senate Blocks Venezuela Measure The Senate has blocked a measure to limit military action by the Trump administration against Venezuela.   Hoagie Hurler Cleared Justice is served for a man who hurled a hoagie at a federal immigration agent in Washington.  The details from correspondent Jennifer King.     Latest On SNAP & Government Shutdown Senators appear closer to ending the government shutdown, now in its 38th day, as a vote is expected later today on a deal that could re-open the government, but it's far from certain enough Democrats are on board.  John Stolnis has more from Washington.   Virginia Teacher's Day In Court A jury awarded $10 million dollars in a civil case to a Virginia teacher who was shot by a first grade student in 2023.  As correspondent Haya Panjwani reports Abagail Zwerner still has a bullet inside her chest from that shooting, and her legal team, speaking outside the courthouse, says her long ordeal is far from over – audio courtesy of Court TV.   Heritage Foundation Fallout The fallout continues surrounding the conservative think tank The Heritage Foundation following an interview by Tucker Carlson with Nick Fuentes.  Correspondent Clayton Neville reports.   SCOTUS On Passports The Supreme Court on Thursday allowed the Trump administration to require the sex designation on US passports to align with a traveler's biological sex, a blow to transgender and non-binary Americans who have argued the policy is unconstitutional.   Trump's Drug Deal At the White House, President Trump unveiled a new deal to expand coverage and lower costs on obesity drugs including Wegovy and Zepbound.  Lisa Dwyer reports.    New Member Of Abraham Accords The White House announced that Kazakhstan will agree to normalizing relations with Israel and join the Abraham Accords, joining the United Arab Emirates, Bahrain, and Morocco who formalized relations with Israel during President Trump's first term in office. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Trump unveils deal to expand coverage and lower costs on obesity drugs Wegovy and Zepbound. AP's Lisa Dwyer reports.

New York's mayor-elect, Zohran Mamdani, is promising to tackle the city's soaring cost of living. Ed Butler looks at what his victory could mean for businesses.Also, Eli Lilly and Novo Nordisk agree to slash the cost of blockbuster weight-loss drugs like Ozempic and Wegovy under a new Medicare deal. And why Shein is facing a backlash in France.

GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® are changing the weight-loss landscape, but there's more to the journey than watching the scale move. In this episode, we break down 4 essential considerations everyone on a GLP-1 should know.With Mindy's science-based and trustworthy expertise, these are the considerations to protect your health during and after medication use:1. Preventing Lean Muscle Mass loss and Osteoporosis2. Managing GI Issues3. Preventing nutrient deficiencies 4. Build Healthy HabitsThis episode is supportive, judgment-free, and packed with actionable takeaways. Whether you're on a GLP-1, considering one, or supporting someone who is, this conversation will leave you feeling empowered and informed. References:Wong, ND, et al. US Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2023Wong, ND, et al.  Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2024 Chakhtoura, M., et al. Pharmacotherapy of obesity: EClinicalMedicine, 2023 Volek J, et al. Nutritional Considerations During Major Weight Loss.  Curr Nutr Rep. 2024Meslon E, et al.  What is the pipeline for future medications in obesity? Nature. 2024Martin CK, et al.  Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.  Nat Med. 2025Dilly A, et al.  Characteristics and food consumption for current, previous, and potential consumers of GLP-1s.  Food Quality and Preference.  2025;129;105507We are so glad you are here. Want to stay in touch?Follow us on social media: Sweat and Laughter podcast - @sweat.and.laughter.podcast Mindy - @strongover40_dietitian Cheryl - @training.with.cheryl Mindy & Cheryl - @mcfitadventures Email us: mcfitadventures@gmail.com Thank you so much for listening to Sweat & Laughter. M & C

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. See omnystudio.com/listener for privacy information.

Just over 18,000 New Zealanders have been prescribed the weight-loss drug Wegovy in the past three months, according to provisional data from Health New Zealand. Weight loss specialist, Doctor Gerard McQuinlan spoke to Ingrid Hipkiss.

Are you doing "everything right"—eating clean, working out, and still battling fatigue, weight loss resistance, and relentless cravings? You're not alone. As women in perimenopause and menopause, shifting hormone balance can slow metabolism, alter hunger cues, and make it nearly impossible to lose weight the way we used to. In this episode, I sit down with Sarah Kennedy, CEO of Calocurb, to talk about a groundbreaking natural alternative to popular GLP-1 weight-loss drugs like Ozempic and Wegovy. We unpack how your body's own gut-brain connection can be reactivated using a 100% natural compound derived from hops, how GLP-1 hormones regulate hunger and satiety, and why this may be one of the most exciting breakthroughs for sustainable weight management—especially for women struggling with perimenopausal weight gain, fatigue, and digestive issues. What You'll Learn • The truth about GLP-1 hormones — what they do in your body, and how they naturally control appetite and fullness. • Why synthetic injectables like Ozempic can cause side effects — and how they differ from your body's own GLP-1 response. • The surprising power of bitter compounds — how natural plant extracts like Amarasate activate GLP-1, reduce cravings, and support a healthy gut-brain axis. • Why this approach is ideal for perimenopausal and menopausal women — discover how hormonal shifts, stress, and low energy change hunger and metabolism, and how to rebalance them naturally. • A simple timing strategy — when to take Calocurb to reduce nighttime cravings, support fasting, and eat less without feeling deprived. If you've been frustrated by weight loss resistance, low energy, or the feeling that your metabolism has "stopped working," this episode will show you why it's not your fault—and how to work with your body instead of against it. We'll walk through the science, the clinical research, and real-world strategies to help you reclaim your energy, rebalance your hormones, and restore your confidence without relying on synthetic solutions. Where you can find out more about Calocurb: www.calocurb.com use code MEG10 to save 10% https://www.facebook.com/calocurbGLOBAL/https://www.instagram.com/calocurb www.calocurb.com Stop wasting time (and money) on products that don't work. My Trusted Brands Guide is the exact list I share with my private clients — the skincare, supplements, food, and wellness tools that have been tested and proven to deliver results. No fluff. No guesswork. Just the brands you can finally feel good about using. ✨ Plus, I scored exclusive discounts from some of these companies just for my community.

Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to the Dr. Kinney Show!In this solo episode, I'm diving deep into one of the most talked-about topics in wellness right now, GLP-1 medications, including Ozempic, Wegovy, and semaglutide. There's a lot of information (and misinformation) circulating about these drugs, and I want to explain how they actually work, when they can be incredibly effective, and when they can cause more harm than good.I break down the glucose-insulin connection, what insulin resistance really means, and why inflammation often begins with blood sugar imbalance. I also share how these medications can be used as a powerful tool for improving insulin sensitivity, reducing inflammation, and supporting hormone balance, when used thoughtfully and at the right time.In this episode, I discuss:How glucose and insulin function together to fuel your bodyWhat happens when insulin resistance develops and why it leads to fatigue, weight gain, and inflammationHow GLP-1 medications like semaglutide work to increase insulin sensitivityWhy microdosing or using the lowest therapeutic dose can be safer and more effectiveThe difference between short-term weight loss and long-term metabolic healthCommon side effects and how to avoid them with proper dosing and timingThe importance of building muscle and eating enough protein before starting a GLP-1 medicationHow these medications can reduce “food noise” and improve mental clarityThe unexpected benefits for hormone balance, PCOS, and menopause symptomsWhy GLP-1s should be seen as a supportive tool, not a quick fixWhether you're curious about GLP-1 medications for weight management, inflammation, or metabolic health, this episode will help you understand how to use them in a way that truly supports your body's healing process.https://www.thekinneyclinic.com/book

Lately, it feels like everyone is talking about food noise. Thanks to GLP-1 medications like Ozempic and Wegovy, "food noise" has become the latest buzzword — and the newest thing people believe needs to be fixed with medication. But here's the truth: most people don't have a medical disorder that causes food noise. They have a body and mind that feel unsafe. Food noise isn't a disease — it's a signal. It's your body saying, "I don't trust you to feed me." In this week's episode, Deanna breaks down what's really behind constant thoughts about food, why medicating symptoms doesn't fix the cause, and what it actually takes to quiet food noise naturally — no prescription required. In this episode — "How to Stop Food Noise Without Medication" — you'll learn:

In part 2 of this GLP-1 series, Ted shares two real-life case studies that reveal when weight loss drugs like Ozempic, Wegovy, and Mounjaro deliver results—and when they don't. Discover the surprising lessons that make the difference. If you missed part 1, go back to hear Ted break down the dos and don'ts of these drugs, how they work, the results people are seeing, and the lifestyle shifts that ensure lasting success. Listen now!  Click here for part 1: